For research use only. Not for therapeutic Use.
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache[1].
BGC-20-1531 free base competitively antagonized PGE2-induced vasodilatation of human middle cerebral (pKb=7.8) and meningeal (pKb=7.6) arteries, but had no effect on responses induced by PGE2 on coronary, pulmonary or renal arteries[1].
BGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow[1].
| Catalog Number | I045050 |
| CAS Number | 736183-35-0 |
| Synonyms | 4-[[4-(5-methoxypyridin-2-yl)phenoxy]methyl]-5-methyl-N-(2-methylphenyl)sulfonylfuran-2-carboxamide |
| Molecular Formula | C26H24N2O6S |
| Purity | ≥95% |
| InChI | InChI=1S/C26H24N2O6S/c1-17-6-4-5-7-25(17)35(30,31)28-26(29)24-14-20(18(2)34-24)16-33-21-10-8-19(9-11-21)23-13-12-22(32-3)15-27-23/h4-15H,16H2,1-3H3,(H,28,29) |
| InChIKey | IXDVRRPNWPOPGV-UHFFFAOYSA-N |
| SMILES | CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(O2)C)COC3=CC=C(C=C3)C4=NC=C(C=C4)OC |
| Reference | [1]. Maubach KA, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009;156(2):316-327. |
